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16 Oral PresentationsCD141 cellswere also noted inbothCD341 andMNCrecipientmice
(p# 0.05, n5 3). No significant change in CD191 cells was noted in
any treatment group. This data suggests that UC-MSC have the abil-
ity to enhance short term myeloid reconstitution. It may therefore be
possible to develop UC-MSCmethodologies to both improve ex vivo
CB culture and increase transplant efficiency. Additionally, it may be
preferred that CB HSC and MSC be genetically identical or from an
HLA-matched or unmatched non-adult MSC tissue source.36
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Cord blood (CB) provides a readily available, ethnically-diverse
source of hematopoietic tissue for transplantation, however, low
cell dose delays engraftment and increases risk of graft failure. In ad-
dition, it has also been suggested that CB hematopoietic stem cells
(HSC) home less efficiently to the hematopoietic microenvironment
after transplantation when compared to bone marrow or peripheral
blood HSC. Homing mechanisms may rely, at least in part, on the
interaction between fucosylated glycoproteins on the surface of
HSC and P- and E-selectins expressed by the microvasculature of
the hematopoietic system. Glycoproteins expressed on the surface
of CB HSC appear to be poorly fucosylated. It has been proposed
that the use of a fucosyltransferase (FT) to increase levels of surface
glycoprotein fucosylation may improve homing to the bone marrow
and thereby improve engraftment. In an initial series of experiments,
levels of fucosylation of surface glycoproteins expressed on CB
CD341 cells were increased using FT-VI (Engraftin, America
Stem Cell). When subsequently injected into an NOD-SCID IL-
2Rgnull mouse model, the rate and magnitude of human engraftment
was greater than in mice receiving a similar dose of untreated CB
CD341 cells. Since CB recipients receive mononuclear cells
(MNC) rather than selected CD341 cells, the efficacy of a fucosyla-
tion strategy using CB MNC was investigated.
Methods: MNC were obtained from a frozen CB unit. Half was
untreated and half fucosylated: incubation for 30 minutes at room
temperature with 1 mM GDP b-Fucose, 1 mM MnCl2 and FT-
VI. Fucosylated and untreated MNC were washed and each trans-
planted into sublethally-irradiated (270 cGy) NOD-SCID
IL-2Rgnull mice (5 mice/gp). Mice each received 6  106 CB
MNC (containing 2.5 104 CD341 cells) by tail vein injection. En-
graftment was followed at weekly intervals by flow cytometric mea-
surement of human CD451 cells in the peripheral blood.
Results: 6 weeks after transplantation, recipients of fucosylated
MNC showed a maximal 14% human engraftment, as compared to
1% in recipients of untreated MNC.
Conclusion: Consistent with preliminary data following trans-
plantation of fucosylated, or untreatedCBCD341 cells, fucosylation
of CB MNC appears to improve both the rate and magnitude of en-
graftment. The efficacy of this technology will be explored in both
the single and double CB transplant settings and a clinical trial eval-
uating this approach will be designed and executed.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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PRE-ENGRAFTMENT SYNDROME (PES): A CLINICAL SYNDROME AFTER
CORD BLOOD (CB) TRANSPLANTATION NOT ASSOCIATED WITH ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) OR TRANSPLANT-RELATED
MORTALITY (TRM)
Patel, K.J., Rice, R.D., Hawke, R.M., Abboud, M., Heller, G.,
Scaradavou, A., Barker, J.N. Memorial Sloan-Kettering Cancer Center,
New York, NYPre-Engraftment Syndrome after cord blood transplantation
(CBT) is poorly characterized. Therefore, we conducted a review
of 52 double unit CBT recipients treated for high-risk hematological
malignancies to determine the incidence, manifestations, and
outcomes of PES. PES was defined as unexplained fever .38.3oC
(101oF) unresponsive to antibiotics and/or unexplained skin rash re-
sembling aGVHDoccurring prior to or at neutrophil recovery. CBT
recipients [median 38 years (range 3–66)] received either ablative (n
5 36) or non-myeloablative (NMA, n5 16) conditioning and CSA/
MMF. The cumulative incidence (CI) of sustained donor engraft-
mentwas 94% (95%CI:88–100)with neutrophil recovery at amedian
of 25 days in ablative and 11 days in NMA recipients. The CI of day
100 grade II-IV aGVHD and day 180 TRM were 40% (95%CI:
27–53) and 24% (95%CI:13–35), respectively. Sixteen (31%) pa-
tients fulfilled PES criteria: 15 with fever [median 39oC/102.2oF
(range 38.4–39.4oC) at onset] at a median of 9 days (range 5–12)
with 13 of these also having rash, and 1 having rash alone. The re-
maining 36 ‘‘no PES’’ patients included 5 without fever or rash, 26
with fever due to infection, and 5 with fever thought to be due to in-
fection and possible PES. Sixteen received IV methylprednisolone
(MP) treatment [14 PES, 2 with infection and possible PES; median
dose 1 mg/kg (range 0.5–2), median duration 3 days (range 2–44)].
Of 16 MP treated patients, 15 had fever resolution in #24 hours
and 1 in\48 hours. Two non-treated patients included 1 with spon-
taneous resolution of rash and 1 who remained febrile for 33 days.
While 3 patients had recurrent fever attributed to PES after MP ces-
sation this resolvedwith brief re-treatment. There was no association
between patient demographics, conditioning, or graft characteristics
and development of PES. There was also no association between
PES and neutrophil recovery, graft failure, aGVHD, or day 180
TRM.
Association between PES and Transplant Outcome
Median Grade 2-4
Total
(N 5 52)
Day Neutrophil
Recovery
Graft
FailureaGVHD
d 1 100 TRM d 1 100PES n516
(31%)Ablative
(n512):
23 days
(range 14-33);
NMA
(n54): 22 days
(range 7-36)n52 n55; 50 days
(range 34-70)n54No PES
n536
(69%)Ablative: 25 days
(range 13-43);
NMA: 11
days (range 7-22)n52 n514; 41 days
(range 29-99)n54p 5 0.75 p 5 0.67 p 5 0.79 p 5 0.22Eleven (69%) PES patients developed hypoxia6 pulmonary infil-
trates at a median of 12 days (range 7–15) as compared to 16 (44%)
non-PES patients (p 5 0.138). In summary, PES is common after
CBT, precedes neutrophil engraftment, is distinct from and does
not predict for aGVHD, and responds promptly to short course ste-
roids. Patients should not be diagnosed with early aGVHD or
treated with extended courses of steroids. Further investigation of
the etiology of PES and the toxicity (especially pulmonary
manifestations) is indicated.38
CORD BLOOD (CB) EXTENDS TRANSPLANT ACCESS TO RACIAL AND ETH-
NIC MINORITIES: A PROSPECTIVE STUDY OF 309 UNRELATED SEARCHES
IN PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES
Lee, S.S., Scaradavou, A., Hawke, R.M., Webb, K.A., Wells, D.S.,
Abboud, M., Papadopoulos, E.B., Kernan, N.A., Barker, J.N. Memorial
Sloan-Kettering Cancer Center, New York, NY
HLA-A,B,C,DRB1 allelematch improves unrelated donor (URD)
hematopoietic stem cell (HSC) transplant outcome but limits the
number of suitable donors. In contrast, CB transplantation (CBT)
is associated with a reduced HLA-match requirement. Therefore,
we prospectively evaluated donor availability in 309 patients [median
